Startups, philanthropy, billionaires, academia, neuromodulation, psychedelics, AI and new therapies in bipolar, autism, and Parkinson’s with Rob Malenka
Impossibile aggiungere al carrello
Puoi avere soltanto 50 titoli nel carrello per il checkout.
Riprova più tardi
Riprova più tardi
Rimozione dalla Lista desideri non riuscita.
Riprova più tardi
Non è stato possibile aggiungere il titolo alla Libreria
Per favore riprova
Non è stato possibile seguire il Podcast
Per favore riprova
Esecuzione del comando Non seguire più non riuscita
Startups, philanthropy, billionaires, academia, neuromodulation, psychedelics, AI and new therapies in bipolar, autism, and Parkinson’s with Rob Malenka
-
Letto da:
-
Di:
A proposito di questo titolo
Matias interviews Rob Malenka.
In this episode, we discuss:
- Why progress in psychiatry is slow because the brain is the most complex organ and many disorders are highly heterogeneous
- The bottlenecks including weak replicability in research, academic politics, perverse incentives, and pharma’s avoidance of neuropsychiatry
- How breakthroughs require early detection, rigorous science, and bridging academia with biotech through venture philanthropy
- How success depends on mission-driven, ethical people who align science, capital, and patient impact.
- The opportunities in neuromodulation, data-driven precision medicine, and combination therapies.
Credits:
Created by Greg Kubin and Matias Serebrinsky
Host: Matias Serebrinsky
Produced by Caitlin Ner & Nico V. Rey
Find us at businesstrip.fm and psymed.ventures
Follow us on Instagram and Twitter!
Theme music by Dorian Love
Additional Music: Distant Daze by Zack Frank
Ancora nessuna recensione